Clinical trial
A Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multi-Center Phase 2 Study to Evaluate the Efficacy, Safety, and Tolerability of Once-Weekly CT-388 Administered for 48 Weeks to Participants With Obesity or Overweight With at Least One Weight-Related Comorbidity
NCT06525935 is registered in ClinicalTrials.gov with Carmot Therapeutics, Inc. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multi-Center Phase 2 Study to Evaluate the Efficacy, Safety, and Tolerability of Once-Weekly CT-388 Administered for 48 Weeks to Participants With Obesity or Overweight With at Least One Weight-Related Comorbidity
- Lead sponsor
- Carmot Therapeutics, Inc.
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- August 16, 2024
- Completion date
- December 8, 2025
- Enrollment
- 469 (actual)
- Sites
- 34
Conditions
As the registry lists them; a condition with its own page is linked.